Fungal Assay Portfolio Expansion
Fungal Infections
DevelopmentActive
Key Facts
About PathoFinder
PathoFinder is a privately held Dutch diagnostics company founded in 2004 (operationally noted as 2010) that has established itself in the syndromic molecular testing market. It leverages proprietary multiplex PCR technologies, primarily its 2SmartFinder® platform, to detect up to 24 pathogens in a single assay, aiming to improve patient outcomes through rapid, comprehensive infectious disease diagnostics. The company is commercial-stage, with a portfolio of CE-marked IVD kits distributed globally, and maintains ISO 13485:2016 and IVDR certifications. Its strategy focuses on expanding its assay menu, particularly in fungal diagnostics, and transitioning to automated platforms to solidify market leadership.
View full company profileTherapeutic Areas
Other Fungal Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Liposomal Amphotericin B | Bharat Serums & Vaccines | Commercial |
| Caspofungin | BDR Pharmaceuticals | Commercial |
| Rapid Anti-Fungal Susceptibility Test | Affinity Biosensors | Research |
| Clotri-Denk | Denk Pharma | Approved |
| Ibrexafungerp (Scynexis Partnership) | Ligand Pharmaceuticals | Marketed |